Drugs / RGL-270
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT06685653 | ? → Nov 2026 expected | non-small cell lung carcinoma | Nanjing Tianyinshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT07348042 | Sep 2025 → Mar 2027 expected | — | Xian-Jun Yu | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07652125 | Oct 2025 → Dec 2027 expected | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RGL-270 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07652125 ↗ |
| Modality | Messenger RNA (mRNA) | “personalized mRNA tumor vaccine RGL-270” NCT06685653 ↗ |